View Older Stories View More Recent Stories

Apr 14, 2022 09:07AM CTI BioPharma (CTIC) PT Raised to $5.90 at Stifel with a Buy Rating, Analyst Sees Broadening Commercial Opportunity for VONJO
Apr 14, 2022 08:55AM Cowen Reiterates Outperform Rating on Evelo Biosciences (EVLO) Despite Focus Shift
Apr 14, 2022 08:28AM Mizuho Securities Reiterates Buy Rating, $57 Price Target on Xencor (XNCR), Sees Upcoming plamotamab Study as Potentially Driving Shares to "Therapeutically-driven Valuation"
Apr 14, 2022 06:27AM Stifel Reiterates Buy Rating, $10 Price Target on Applied Genetic Technologies (AGTC), Sees Potential for Significant Upside from SKYLINE Trial Readout
Apr 14, 2022 06:04AM Needham & Company Reiterates Buy Rating, $44 Price Target on G1 Therapeutics (GTHX)
Apr 14, 2022 05:54AM Needham & Company Reiterates Buy Rating, $10 Price Target on Mereo BipPharma Group (MREO)
Apr 14, 2022 05:46AM Needham & Company Reiterates Buy Rating, $52 Price Target on Cytokinetics (CYTK)
Apr 14, 2022 05:44AM Needham & Company Reiterates Buy Rating, $36 Price Target on Collegium Pharmaceutical (COLL), Believes "COLL's Current Valuations Fails to Capture Growth Prospects"
Apr 13, 2022 06:14AM H.C. Wainwright Reiterates Buy Rating, $21 Price Target on Alpine Immune Sciences (ALPN), "Data Firmly Justify Expliration of davoceticept"
Apr 13, 2022 06:11AM H.C. Wainwright Reiterates Buy Rating, $13 Price Target on IMV (IMV), "AACR Results Add Confidence to DPX-Based Therapies in Bladder Cancer and Beyond"
Apr 13, 2022 05:50AM Oppenheimer Reiterates Outperform Rating, $17 Price Target on Alpine Immune Sciences (ALPN)
Apr 13, 2022 05:47AM Needham & Company Reiterates Buy Rating, $65 Price Target on Intra-Cellular Therapies (ITCI)
Apr 12, 2022 05:12PM Stifel Reiterates Buy Rating on Eliem Therapeutics (ELYM), Sees Positive Risk/Reward Ahead of Upcoming ETX-810 Readouts
Apr 12, 2022 04:43PM Stifel Reiterates Fulcrum Therapeutics (FULC) at Buy Despite Recent Weakness, Sees no Change to Thesis/Outlook
Apr 12, 2022 10:01AM Kintara Therapeutics (KTRA) PT Slashed to $3 at Dawson James on Dilution,
Apr 12, 2022 09:09AM Brookline Capital Markets Reiterates Buy Rating, $15 Price Target on MEI Pharma (MEIP), Sees "Upside to Longer-Term Outlook" from ME-344 Contributions
Apr 12, 2022 08:16AM Cantor Fitzgerald Reiterates Overweight Rating, $95 Price Target on I-Mab (IMAB), Expects "Greater Appreciation for the Company's Pipeline"
Apr 12, 2022 08:09AM Needham & Company Reiterates Aeglea Biotherapeutics (AGLE) at Buy with $12 Price Target, Maintains "pegzilarginase Data Will Be Sufficient for Approval"
Apr 12, 2022 07:12AM Needham & Company Reiterates Buy Rating, $85 Price Target on I-Mab (IMAB)
Apr 12, 2022 06:45AM Needham & Company Reiterates Nurix (NRIX) at Buy with $48 Price Target
Apr 12, 2022 06:37AM Needham & Company Reiterates Buy Rating, $48 Price Target on Xenon Pharmaceuticals (XENE), Sees 70% Probability of Success for XEN1101
Apr 12, 2022 06:35AM Needham & Company Reiterates Buy Rating, $32 Price Target on Taysha Gene Therapies (TSHA)
Apr 12, 2022 06:26AM Sabizabulin on "Short Path to FDA EMA", Will "Serve Critical Roles in the US and Abroad" - Veru (VERU) PT Hiked to $36 at Oppenheimer,
Apr 12, 2022 06:20AM Needham & Company Reiterates Buy Rating on Rocket Pharmaceuticals (RCKT), Sees RP-A501 as "Major Value Driver"
Apr 12, 2022 06:18AM Needham & Company Reiterates Buy Rating, $31 Price Target on Shattuck Labs (STTK)
Apr 12, 2022 06:17AM Needham & Company Reiterates Generation Bio (GBIO) at Buy with $27 PT, "Technology Has Potential to Overcome Key Obstacles in Gene Therapy... Generation is a Potential Acquisition Target"
Apr 12, 2022 06:12AM H.C. Wainwright Reiterates Neutral Rating on Nabriva Therapeutics (NBRV) Due to Financing Overhang
Apr 12, 2022 06:08AM Bicycle Therapeutics (BCYC) PT Lowered to $75 at Needham & Company on Toxicity Limitations, But Reiterates Competitiveness and Differentiation of BT8009
Apr 12, 2022 06:05AM Needham & Company Reiterates Buy Rating, $57 Price Target on Harmony Biosciences Holdings Inc. (HRMY)
Apr 12, 2022 05:57AM Needham & Company Reiterates Avadel Pharmaceuticals (AVDL) at Buy with $15 PT, "Incrementally More Positive on AVDL" Following Recent Management Chat
Apr 12, 2022 05:55AM Syros Pharmaceuticals (SYRS) Reiterated at Buy by Brookline Capital Markets, Sees Additional Upside from CDK12
Apr 12, 2022 05:53AM Heron Therapeutics (HRTX) and Omeros (OMER) Top Cantor Fitzgerald's Most Shorted List; Clarus (CRXT) and United Therapeutics (UTHR) Seeing Biggest Short Interest Increases
Apr 11, 2022 07:55AM Brookline Capital Markets Reiterates X4 Pharmaceuticals (XFOR) at Buy with $13 PT, Sees Peak Mavorixafor Sales of $450.9M
Apr 11, 2022 06:44AM TCR2 Therapeutics (TCRR) Reiterated at Buy with $20 Price Target by Mizuho Securities, Sees Preclinical TRuC-T Data as "Encouraging and Supportive"
Apr 11, 2022 06:26AM Mizuho Securities Reiterates Buy Rating, $51 Price Target on Arcus Biosciences (RCUS), Believes Next Wave of Pipeline Assets is "Yet to Be Fully Incorporated into Valuation"
Apr 11, 2022 06:23AM Pfizer's (PFE) Paxlovid and Comirnaty Q1 Sales Estimates Lowered at Cantor Fitzgerald, but "Positive Investment Thesis" Maintained, Reiterates Overweight Rating
Apr 11, 2022 06:20AM Stifel Reiterates Buy Rating on Repare Therapeutics (RPTX) on Recent RP-3500 Update
Apr 11, 2022 06:17AM H.C. Wainwright Reiterates Genocea Biosciences (GNCA) at Buy with $9 Price Target, Remains Optimistic of GEN-011 Antitumor Efficacy and Durability, Sees Significant "Value-generating Potential"
Apr 11, 2022 05:56AM Mizuho Securities Reiterates Buy Rating, $12 PT on IN8bio (INAB), Sees Latest Presentations as "Supportive of INAB's Drug-resistant Immunotherapy Platform"
Apr 8, 2022 04:05PM Brookline Capital Markets Reiterates Buy Rating, $143 PT on CRISPR Therapeutics (CRSP) on "Encouraging" New CTX130 Data
Apr 8, 2022 06:47AM Annexon Biosciences (ANNX) PT Lowered to $24 at Needham & Company, but Analyst Reiterated "Promise in ANX007 GA Program", Sees ANX007 MoA as "Intriguing"
Apr 8, 2022 06:11AM H.C. Wainwright Reiterates Neutral Rating, $2 PT on Akebia Therapeutics (AKBA)
Apr 8, 2022 06:07AM Stifel Reiterates Hold Rating on Biogen (BIIB), Notes CMS Decision "Closes The Door" for Aduhelm Coverage
Apr 7, 2022 04:44PM Cowen Reiterates Outperform Rating on Aptinyx (APTX), Sees "Better Rationale" for 2925 in Fibromyalgia
Apr 7, 2022 09:22AM Brookline Capital Markets Reiterates Moderna (MRNA) at Buy, Believes Expanded IAVI Partnership May Provide Upside to Longer Term Outlook
Apr 7, 2022 09:08AM Cantor Fitzgerald Reiterates VYNE Therapeutics (VYNE) at Overweight with $10 PT, Sees Latest FMX114 Data Underscoring "Positive Investment Thesis"
Apr 7, 2022 08:18AM BMO Capital Reiterates Outperform Rating on Pfizer (PFE) but Does Not See ReViral Acquisition "Impactful for Pfizer's Nearer-Term P&L"
Apr 7, 2022 08:16AM Aptinyx (APTX) PT Lowered to $5 at Truist Securities, but Reiterates Buy, Notes Stock Trades Near Cash Assigning no Credit to NYX-458 in PDCI
Apr 7, 2022 07:38AM Truist Securities Reiterates Buy Rating on Pfizer (PFE) Following ReViral Acquisition, Sees is "Potential Return to M&A"
Apr 7, 2022 06:19AM Cantor Fitzgerald Reiterates Overweight Rating, $75 Price Target on Pfizer (PFE), Sees Strong Pipeline and M&A Potential Driving PFE Higher
View More Recent Stories View Older Stories